Shares of Health Care sector company BioMarin Pharmaceutical moved 0.7% today, and are now trading at a price of $62.46. The ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

First Quarter 2025 Results Key Financial Results Revenue: US$745.1m (up ...

Q1 2025 Earnings Call Transcript May 1, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $1.13, ...

Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

Compared to the aggregate P/E ratio of the 52.0 in the Biotechnology industry, Biomarin Pharmaceutical Inc. has a lower P/E ...

Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President - Finance; Biomarin Pharmaceutical Inc ...

Discover BioMarin's Q1 2025 highlights: 15% revenue growth, VOXZOGO's 40% surge, and innovative R&D initiatives.

On the call from BioMarin management today are Alexander Hardy, President and Chief Executive Officer; Brian Mueller, Executive Vice President, Chief Financial Officer; Cristin Hubbard, Executive Vice ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago.

SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported first-quarter net income of $185.7 million. The San Rafael, California-based company said ...